Bloomage BioTechnology Corporation Limited (SHA: 688363)

Market Cap	29.09B
Revenue (ttm)	5.73B
Net Income (ttm)	440.18M
Shares Out	478.36M
EPS (ttm)	0.91
PE Ratio	66.77
Forward PE	41.45
Dividend	0.38 (0.63%)
Ex-Dividend Date	Aug 8, 2024

Volume	3,468,720
Open	60.93
Previous Close	60.80
Day's Range	59.05 - 61.73
52-Week Range	44.72 - 84.59
Beta	0.84
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Bloomage BioTechnology Corporation

Bloomage BioTechnology Corporation Limited researchers, develops, produces, and sells bioactive materials. It offers pharmaceutical grade sodium hyaluronate which can be used as an API or excipient for drugs and medical devices in ophthalmic preparations, intra-articular injections, anti-adhesive preparations, and topical preparations for wound healing and soft tissue filler under the Hyature name; and cosmetic grade sodium hyaluronate solutions for cosmetic products, including moisturizing, repairing, delay skin aging, and brightening under th...

• Industry: Specialty Chemicals
• Sector: Materials
• Founded: 2000
• Employees: 4,655
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688363

Financial Performance

In 2023, Bloomage BioTechnology Corporation's revenue was 6.08 billion, a decrease of -4.45% compared to the previous year's 6.36 billion. Earnings were 592.56 million, a decrease of -38.97%.